(Teva Pharmaceuticals) Preclinical in vivo characterization of the anti-tumor activity of a non-blocking PD-1 antibody fused to attenuated IL-2

Anti-tumor immunotherapy

November 21, 2024

Abstract

  • TEV-56278 is a fusion protein developed by Teva, combining a non-blocking anti-PD1 antibody with an attenuated IL-2 variant. This design targets IL-2 to PD-1+ T cells, aiming to enhance anti-tumor immunity while minimizing systemic IL-2 side effects.
  • IL-2 is crucial for immune regulation, as it enhances T cell proliferation and activation, thereby boosting anti-tumor immunity. However, its clinical use is limited by systemic toxicity and a narrow therapeutic window (Atkins et al., 1999). TEV-56278 features an attenuated IL-2 moiety, developed to mitigate these risks.
  • PD-1 expression is significantly higher in tumor-infiltrating T cells compared to circulating and other tissue-resident T cells (Ahmadzadeh et al., 2009). TEV-56278's design allows the IL-2 variant to target PD-1-expressing cells while preserving PD-1 receptor functionality. This enables treatment both as a monotherapy and in combination with an anti-PD1 antibody.
  • Here, we describe the impact of TEV-56278 and its murine surrogate, mAnti-PD1-IL2, on tumor progression and tumor-infiltrating lymphocytes in pre-clinical tumor models.

Related products

Catalogue product

genO‑BRGSF‑HIS

genO‑BRGSF‑HIS mice possess the most functional reconstituted human immune system currently on the market and are highly relevant for translational research.

Customized product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe